Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
14 déc. 2023 08h00 HE
|
Phathom Pharmaceuticals
Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027Up to an additional $100 million in non-dilutive capital...
Gastroesophageal Reflux Disease Market to Grow at a Substantial Growth Rate by 2032 - DelveInsight | Key Companies in the Market - Phathom Pharmaceuticals, Microbiome Health Sciences, Takeda, Braintree Laboratories, AstraZeneca
12 déc. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Gastroesophageal Reflux Disease Market to Grow at a Substantial Growth Rate by 2032 - DelveInsight | Key Companies in the Market - Phathom...
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
06 déc. 2023 08h00 HE
|
Phathom Pharmaceuticals
New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly...
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
28 nov. 2023 08h00 HE
|
Phathom Pharmaceuticals
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available at major retail pharmacies and through BlinkRx.
Microbiome Therapeutics Market Size to Hit $813.38 Million, Globally, by 2030 - Exclusive Report by The Insight Partners
10 nov. 2023 05h43 HE
|
The Insight Partners
Pune, India, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that try to use the human microbiome's...
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
09 nov. 2023 08h00 HE
|
Phathom Pharmaceuticals
VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
01 nov. 2023 17h00 HE
|
Phathom Pharmaceuticals
FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 yearsVOQUEZNA® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3...
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
26 sept. 2023 08h01 HE
|
Phathom Pharmaceuticals
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile...
4.9% CAGR for Gastrointestinal Drugs Market Size Worth $71.3Bn, Globally, by 2027 with Irritable Bowel Syndrome Segment Driving Growth During 2020-2027 | Report by The Insight Partners
11 juil. 2023 10h55 HE
|
The Insight Partners
Pune, India, July 11, 2023 (GLOBE NEWSWIRE) -- The Insight Partners latest study on "Gastrointestinal Drugs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug...
Global Pediatric Gastroenterology Market Size & Trends
23 juin 2023 10h59 HE
|
Global Market Estimates
Brooklyn, New York, June 23, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Pediatric Gastroenterology Market is projected to...